3SBio (1530) Fundamentals 2026 — P/E 4.4x, Revenue Analysis | SniperIQ

7.29 on the HKSE. This SniperIQ fundamentals page covers 3SBio's valuation (P/E 4.4x, P/B 1.4x), profitability (net margin 47.9%), revenue (¥17.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is 3SBio's market cap?

3SBio (1530) has a market capitalization of approximately HK$43.2B, trading at HK

7.29 on the HKSE. Market cap moves with the live share price.

What is 3SBio's P/E ratio?

3SBio's trailing twelve-month P/E ratio is 4.4x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is 3SBio?

3SBio runs a net profit margin of 47.9%, a gross margin of 92.4%, and an operating margin of 59.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does 3SBio generate?

3SBio reported revenue of ¥17.7B for fiscal year 2025, with net income of ¥8.5B and earnings per share (EPS) of 3.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does 3SBio pay a dividend?

3SBio offers a trailing dividend yield of about 1.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is 3SBio financially healthy?

3SBio carries a debt-to-equity ratio of 0.10x and a current ratio of 5.13x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is 3SBio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For 3SBio (1530) the key facts are: market cap HK$43.2B, P/E 4.4x, revenue ¥17.7B, 52-week range 14.81-36.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.